Indonesia, one of the first nations to bet its Covid-19 vaccination campaign on Sinovac Biotech Ltd., was about to announce a stunning development, one that would help vindicate a shot that’s been shrouded in controversy for months.
Chinese shot takes controversial path to vaccinating the world Sorry, but your browser needs Javascript to use this site. If you re not sure how to activate it, please refer to this site: https://www.enable-javascript.com/
People stand in a queue as they wait to get a dose of the Chinese-made Sinopharm COVID-19 vaccine in Piliyandala, on the outskirts of Colombo, Sri Lanka. | AFP-JIJI
Bloomberg May 13, 2021
Indonesia, one of the first nations to bet its COVID-19 vaccination campaign on Sinovac Biotech Ltd., was about to announce a stunning development, one that would help vindicate a shot that’s been shrouded in controversy for months. Over in Beijing, though, the company’s chief executive officer was unaware.
Indonesia, one of the first nations to bet its Covid-19 vaccination campaign on Sinovac Biotech Ltd., was about to announce a stunning development, one that would help vindicate a shot that’s been shrouded in controversy for months. Over in Beijing, though, the company’s chief executive officer was unaware. A study of some 128,000 Jakarta health workers released Wednesday found Sinovac’s vaccine known as CoronaVac was far more protective than clinical trials had indicated. A day earlier, it wasn’t mentioned by CEO Yin Weidong in a wide-ranging interview with Bloomberg reporters, and representatives later confirmed the company didn’t know the announcement was coming.
The World Finally Accepts a Much-Maligned Covid Shot
Bloomberg 2 hrs ago
Indonesia, one of the first nations to bet its Covid-19 vaccination campaign on Sinovac Biotech Ltd., was about to announce a stunning development, one that would help vindicate a shot that’s been shrouded in controversy for months. Over in Beijing, though, the company’s chief executive officer was unaware.
A study of some 128,000 Jakarta health workers released Wednesday found Sinovac’s vaccine known as CoronaVac was far more protective than clinical trials had indicated. A day earlier, it wasn’t mentioned by CEO Yin Weidong in a wide-ranging interview with Bloomberg reporters, and representatives later confirmed the company didn’t know the announcement was coming.
91 A healthcare worker prepares a dose of Sinovac s vaccine for the coronavirus disease during a mass vaccination for medical workers at the Istora Senayan stadium in Jakarta on Feb 4 this year. (Reuters photo)
Indonesia, one of the first nations to bet its Covid-19 vaccination campaign on Sinovac Biotech, was about to announce a stunning development, one that would help vindicate a shot that’s been shrouded in controversy for months. Over in Beijing, though, the company’s chief executive officer was unaware.
A study of some 128,000 Jakarta health workers released Wednesday found Sinovac’s vaccine known as CoronaVac was far more protective than clinical trials had indicated.